AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03560011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunoglobulin IV
Description: 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)
Study NCT03318003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-PAP
Description: Women will be using the Auto-PAP device nightly from randomization to end of pregnancy
Study NCT01968811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance Foam dressing kit
Study NCT04190862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-CEL UVEC
Description: Injection of E-CEL UVEC
Study NCT03118817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM95573
Description: Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops
Study NCT01241708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.6mg/m2 on day -4 and day -1
Study NCT01535313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OnControl BM-Biopsy system
Description: Bone marrow biopsy at posterior iliac crest
Study NCT01535313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OnControl BM-Biopsy system
Description: Bone marrow biopsy at posterior iliac crest
Study NCT00509899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
Study NCT01854697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study NCT01854697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study NCT01854697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Tablet
Study NCT01854697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: Film-coated tablet
Study NCT01854697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon alpha 2-a (PegIFN)
Description: Pre-filled syringe
Study NCT03445000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.~Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose.
Study NCT00715299 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: locomotor training
Description: Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
Study NCT02824146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver
Description: The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (15 cmH2O of PEEP + 15 cmH2O of driving pressure) for 10 breaths.
Study NCT02274597 — intervention group
Intervention type: DEVICE
Intervention: metraux epitympanic thermometer
Description: accuracy of epitympanic temperature measurement in different environmental settings
Study NCT04473872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory rehabilitation
Description: intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.
Study NCT04473872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory rehabilitation
Description: intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.
Study NCT02326272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use
Study NCT02326272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use
Study NCT04009304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OSNAP
Description: Afterschool practice and policy change to support healthy eating and physical activity
Study NCT01870986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06410293
Description: 40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
Study NCT01870986 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira (adalimumab-EU)
Description: 40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
Study NCT01870986 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira (adalimumab-US)
Description: 40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
Study NCT03038529 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Classic postrolateral extraarticular percutaneous approach for O3 injection
Description: Receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through the classic postrolateral extraarticular percutaneous approach
Study NCT03038529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postrolateral transforaminal approach (Yess approach ) for O3 injection
Description: Group B receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach ).
Study NCT01050946 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Haploidentical/cord transplant
Description: Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.~Conditioning Regimens Choice of regimen at the discretion of the treating physician~1. Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)~2. Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)~Day 0 -Haploidentical donor and one umbilical cord blood unit infusion
Study NCT00027885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Patients receive bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
Study NCT00027885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00027885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00027885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
Study NCT00027885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00027885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00027885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.~Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00027885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Description: After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.~Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00027885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.
Study NCT00027885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.
Study NCT00027885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.~Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00027885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy
Description: Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.~Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00027885 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
Study NCT00027885 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
Study NCT03742986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 360mg
Description: Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)
Study NCT03742986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80mg/m^2
Description: Paclitaxel 80mg/m\^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)
Study NCT03742986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60mg/m^2
Description: Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)
Study NCT03742986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600mg/m^2
Description: Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)
Study NCT03742986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2
Description: Paclitaxel 80mg/m\^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m\^2 on Day 1 of every 21 day cycle (Cycle 1-4)
Study NCT03742986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab 8mg/kg and 6 mg/kg
Description: Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4
Study NCT03742986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab 840mg and 420mg
Description: Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4
Study NCT03216707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD tDCS active motor cortex
Description: the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
Study NCT03216707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD tDCS active insula cortex
Description: the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
Study NCT03216707 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD tDCS sham motor cortex
Description: the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
Study NCT03216707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin cream
Description: Capsaicin cream
Study NCT03216707 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Capsaicin cream
Description: Capsaicin cream
Study NCT02879955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + Fructose
Description: Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
Study NCT02879955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
Study NCT02879955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Description: Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
Study NCT02879955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose + Acarbose
Description: Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
Study NCT03249428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Improved Quality of Life of low-income Canadians that smoke tobacco and other substances
Description: Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.
Study NCT04951908 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of TMJ
Study NCT00872521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAD induction
Description: Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 \& 11), Doxorubicin 20 mg/m2 i.v. (D1 \& 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 \& 12)
Study NCT03744637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: Single inhaled dose of MK-5475 120, 165, 240, 300, 360, or 480 ug depending upon randomization
Study NCT03744637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single inhaled dose of placebo to match MK-5475
Study NCT00235573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12, 9 micrograms each, were administered 6 hours apart.
Study NCT05618015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training
Description: Exercises were performed with cable resistance training machine
Study NCT05618015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based progressive resistance training
Description: In the first session, with the help of a physiotherapist, strengthening exercises were shown and taught to the patients. Two weeks after the beginning of the home-based PRT program, patients were called to check whether they were doing the exercises in the home program correctly. After the checking for exercise training, the patients were called by phone every two weeks for follow-up.
Study NCT02975180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Description: The MyndMove FES System (MyndTec Inc., Mississauga, ON) is a fully programmable FES device with eight channels. This system allows motor practice of 17 different reaching and grasping protocols. The muscles stimulated may include the anterior, middle and posterior deltoid, biceps and triceps brachii, flexor digitorum superficialis and profundus, extensor digitorum, thenar eminence, lumbricals, and interossei. The sophistication of this system is unique. In contrast, many of the MyndMove stimulation protocols involve activation of small muscles that are used for fine motor control. The second FES device that will be used is the Odstock 2-channel Stimulator (FES Mobility Ltd., Vancouver, BC). While less sophisticated than the MyndMove system, it is smaller and more portable.
Study NCT02975180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional
Description: Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
Study NCT04653831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Treatment with Pirfenidone as mentioned in the experimental arm description.
Study NCT04653831 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Treatment with SoC as mentioned in the control arm description.
Study NCT02768168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dezocine
Description: receive dezocine 0.1 mg/kg
Study NCT02768168 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: receive matching placebo (equal volume of normal saline)
Study NCT01101750 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Quadrivalent HPV for types 6, 11, 16 and 18
Description: Per standard of care, Gardasil 0.5ml IM injection on day one, month 2, and month 6.~Serum samples on day one, month 3 and month 7.
Study NCT04986241 — intervention group
Intervention type: DRUG
Intervention: Statin
Description: Chronic use of statin prescribed previously by the assistant physician.
Study NCT04986241 — intervention group
Intervention type: OTHER
Intervention: Physical activity
Description: Physically active participants
Study NCT04986241 — intervention group
Intervention type: OTHER
Intervention: Sedentary
Description: Physically inactive or sedentary participants.
Study NCT02595502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JJVC Marketed Contact Lens (Test)
Study NCT02595502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Competitor Marketed Contact Lens (Control)
Study NCT03193632 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: US Muscle layer thickness (MLT) estimation
Description: Three measurements will be made at each of three sites; mid-upper arm, forearm and thigh anteriorly and the mean value will be calculated. Measurement sites will be marked with indelible ink to ensure day-to-day consistency.~1. Thigh: MLT of the quadriceps femoris muscle (M. Vastus intermedius and M. rectus femoris) will be assessed bilaterally~2. Mid-upper arm: Muscle layer thickness will be measured over the biceps,midway between the tip of the acromion and the tip of the olecranon~3. Forearm: A point midway between the antecubital skin crease and the ulnar styloid was marked and muscle thickness down to the interosseus membrane
Study NCT03193632 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: REE estimation by indirect calorimetry
Description: REE will be calculated using indirect calorimetry via metabolic module on General Electric ventilator (Engstrom Carestation and Carescape R860, GE Health care, USA) All indirect calorimetric measurements will be done using standardized technique. Gas calibration will be performed before each measurement, and the measurements will last for at least 30 minutes. Measurements will be taken with the patient lying supine and ventilator settings left unchanged for at least 60 minutes ahead of indirect calorimetry. The REE will be calculated during the first 24 hours of admission to ICU.
Study NCT02727738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: Selenium 80 mg bid for 90 days